Efficacy and safety of rate responsive pacing in patients with coronary artery disease and angina pectoris.
The present study included 17 patients with angina pectoris and coronary artery disease in whom a rate responsive ventricular pacemaker (Medtronic Activitrax) had been implanted. All patients had an exclusively paced rhythm. Single blinded, random, cross-over treadmill tests in the rate responsive pacing mode (VVIR) and in the fixed-rate demand mode (VVI) were performed, with an interval of 4-6 weeks. Mean exercise duration increased by 25% during VVIR pacing. Maximal heart rate increased significantly during VVIR compared to VVI pacing (VVI = 74 +/- 2 bpm, VVIR = 116 +/- 8 bpm, P less than 0.001) as did the rate-pressure product (VVI = 10.850 +/- 1,124, VVIR = 16.628 +/- 2,110, P less than 0.001). Despite improved performance, the number of anginal attacks per week and the nitroglycerin consumption did not show a significant difference between the two pacing modes. It is concluded that rate responsive pacing is beneficial and safe in patients with angina pectoris and coronary artery disease.